Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya
Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya
复制标题
DOI：
10.1002/ijc.23045
复制
发表时间：
2008-01-01
影响因子：
6.4
通讯作者：
Temmerman, Marleen
中科院分区：
文献类型：
--
作者：
De Vuyst, Hugo;Gichangi, Peter;Temmerman, Marleen
为了评估目前可用的针对人乳头瘤病毒（HPV）16和18的疫苗可以预防HIV感染妇女中浸润性宫颈癌（ICC）的比例，我们在肯尼亚内罗毕的ICC妇女中进行了一项横断面研究。51名艾滋病毒阳性妇女与153名艾滋病毒阴性妇女的年龄频率相匹配。使用基于聚合酶链反应的测定法（SPF 10-INNO-LiPA）检测宫颈细胞的HPV DNA。对HPV类型的多样性进行了调整。正如预期的那样，多种类型的感染在HIV阳性（37.2%）比HIV阴性（13.7%）的妇女中更常见，但HPV类型的分布相似。在HIV阳性与HIV阴性妇女中，HPV 16的检出率分别为41.2%和43.8%，HPV 16和/或18的检出率分别为64.7%和60.1%。唯一具有边缘统计学意义的差异是HIV阳性妇女中HPV 52的过量（19.6%对5.2%）和HPV 45的缺乏（7.8%对17.0%）。艾滋病毒阴性的妇女。我们已经能够评估艾滋病毒阳性妇女中数量空前的ICC，但由于我们不知道艾滋病毒感染的年龄，我们不能排除它在生命中发生得太晚，无法影响参与宫颈癌发生的HPV类型。然而，如果我们的研究结果得到证实，他们将表明，目前针对HPV 16和18的疫苗预防ICC的功效在HIV阳性和HIV阴性女性中是相似的，前提是在初次性行为之前接种疫苗。(C)2007 Wiley-Liss，Inc.
To evaluate the fraction of invasive cervical carcinoma (ICC) that could be prevented in HIV-infected women by vaccines currently available against human papillomavirus (HPV)16 and 18, we conducted a cross-sectional study in women with ICC in Nairobi, Kenya. Fifty-one HIV-positive women were frequency-matched by age to 153 HIV-negative women. Cervical cells were tested for HPV DNA using polymerase chain reaction-based assays (SPF10-INNO-LiPA). Comparisons were adjusted for multiplicity of HPV types. As expected, multiple-type infections were much more frequent in HIV-positive (37.2%) than in HIV-negative (13.7%) women, but the distribution of HPV types was similar. HPV16 was detected in 41.2% versus 43.8% and HPV16 and/or 18 in 64.7% versus 60.1% of HIV-positive versus HIV-negative women, respectively. The only differences of borderline statistical significance were an excess of HPV52 (19.6% versus 5.2%) and a lack HPV45 (7.8% versus 17.0%) in HIV-positive women compare., HIV-negative women, respectively. We have been able to assess a unprecedented number of ICCs in HIV-positive women, but as we did not know the age of HIV acquisition, we cannot exclude that it had occurred too late in life to affect the type of HPV involved in cervical carcinogenesis. However, if our findings were confirmed, they would suggest that the efficacy of current vaccines against HPV16 and 18 to prevent ICC is similar in HIV-positive and HIV-negative women, provided vaccination is administered before sexual debut, as recommended. (C) 2007 Wiley-Liss, Inc.